News from intra-cellular therapies, inc A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Mar 18, 2014, 16:00 ET Intra-Cellular Therapies to Announce 2013 Fourth Quarter And Full Year Financial Results and to Host Conference Call on Tuesday, March 25, at 4:30 pm Eastern Time

Intra-Cellular Therapies, Inc. (NASDAQ: ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system...


Mar 10, 2014, 07:30 ET Intra-Cellular Therapies Announces the Appointment of Juan Sanchez, M.D., as Vice President of Corporate Communications and Investor Relations

 Intra-Cellular Therapies, Inc. (NASDAQ: ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous...


Mar 03, 2014, 07:00 ET Intra-Cellular Therapies Announces Initiation of Phase I/II Clinical Trial for ITI-007 in Healthy Geriatric Subjects and Patients with Dementia, Including Alzheimer's Disease

 Intra-Cellular Therapies, Inc. (NASDAQ: ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous...


Feb 26, 2014, 16:00 ET Intra-Cellular Therapies to Present at the Cowen and Company 34th Annual Healthcare Conference

  Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) today announced Dr. Sharon Mates, Ph.D., President and Chief Executive Officer, will present at...


Feb 07, 2014, 08:00 ET Intra-Cellular Therapies to Present at Two Upcoming Healthcare Conferences

 Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) today announced Dr. Sharon Mates, Ph.D., President and Chief Executive Officer, will present at...


Feb 05, 2014, 13:04 ET Intra-Cellular Therapies Announces Completion of Public Offering and Exercise of Option to Purchase Additional Shares

 Intra-Cellular Therapies, Inc. (NASDAQ: ITCI), a biopharmaceutical company focused on the development of therapeutics for CNS disorders, today...


Jan 30, 2014, 21:15 ET Intra-Cellular Therapies Announces Pricing of Public Offering of Common Stock; To Begin Trading on NASDAQ Global Select Market under "ITCI"

 Intra-Cellular Therapies, Inc. (OTCQB: ITCI), a biopharmaceutical company focused on the development of therapeutics for CNS disorders, today...


Dec 19, 2013, 19:25 ET Intra-Cellular Therapies Cleared for Quotation on OTCQB

 Intra-Cellular Therapies, Inc. ("ITI"), a biopharmaceutical company focused on the development of therapeutics for CNS disorders, announced...


Dec 09, 2013, 06:55 ET Intra-Cellular Therapies Announces Positive Topline Phase II Clinical Results of ITI-007 for the Treatment of Schizophrenia

Intra-Cellular Therapies, Inc. ("we," "ITI" or "the Company"), a biopharmaceutical company focused on the development of therapeutics for central...


Sep 03, 2013, 08:00 ET Intra-Cellular Therapies Announces Closing of $60 Million Private Placement and Completion of Reverse Merger

 Intra-Cellular Therapies, Inc. ("ITI" or the "Company"), a biopharmaceutical company focused on the development of therapeutics for CNS...


May 14, 2013, 07:30 ET Intra-Cellular Therapies Appoints Professor Sir Michael Rawlins to its Board of Directors

 Intra-Cellular Therapies, Inc. ("ITI"), a biopharmaceutical company focused on the development of therapeutics for CNS disorders, is pleased...


Feb 19, 2013, 07:30 ET Intra-Cellular Therapies Announces Completion of Phase I Single Rising Dose Trial of First-in-Class Selective Phosphodiesterase 1 (PDE1) Inhibitor and Reports Top-line Safety and Pharmacokinetic Findings

 Intra-Cellular Therapies, Inc. ("ITI") today announced the completion of a Phase I single rising dose study of its phosphodiesterase 1...


Mar 02, 2011, 19:06 ET Intra-Cellular Therapies and Takeda Enter into Worldwide Collaboration to Develop and Commercialize Compounds for Schizophrenia

Intra-Cellular Therapies, Inc. ("ITI") and Takeda Pharmaceutical Company Limited (TSE: 4502, "Takeda"), today announced that they have entered into...


Oct 01, 2010, 07:30 ET Intra-Cellular Therapies Announces Positive Results with ITI-002 in Pre-Clinical Models of Parkinson's Disease

Intra-Cellular Therapies, Inc. today announced results from studies demonstrating the anti-Parkinson and other beneficial effects of ITI-002...


Jul 29, 2010, 09:00 ET Intra-Cellular Therapies Announces the Successful Completion of a Phase Ib/II Study of ITI-007 in Patients with Schizophrenia

Intra-Cellular Therapies, Inc. today announced the results from a Phase Ib/II clinical trial in patients with schizophrenia with ITI-007, the...


Dec 21, 2009, 07:30 ET Intra-Cellular Therapies Announces the Results of a Phase I PET Study for ITI-007 for the Treatment of Schizophrenia and Other Psychiatric Disorders

Intra-Cellular Therapies, Inc. (ITI) announced at a recent conference on neuropsychiatric diseases the results from a recently completed Phase...


Mar 10, 2009, 07:30 ET Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia

'Trial Meets Primary and Key Secondary Endpoints' Intra-Cellular Therapies, Inc. today announced the final results from the ITI-007 Phase II trial...


Jan 13, 2009, 07:30 ET Intra-Cellular Therapies Announces Successful Outcome of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia

"Trial Concluded Early Due to Achievement of Statistical Significance Demonstrated at the Primary Endpoint" Intra-Cellular Therapies, Inc. today...


Apr 09, 2008, 01:00 ET Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007

NEW YORK, April 9, 2008 /PRNewswire/ -- Intra-Cellular Therapies, Inc., today announced additional preclinical data from its ongoing development...


Feb 15, 2008, 00:00 ET Intra-Cellular Therapies Presents Data on Its Schizophrenia and Cognition in Schizophrenia Programs at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders

NEW YORK, Feb. 15 /PRNewswire/ -- Intra-Cellular Therapies, Inc. (ITI), announced the presentation of preclinical data on ITI-007, its...


Dec 20, 2007, 00:00 ET Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia

NEW YORK, Dec. 20 /PRNewswire/ -- Intra-Cellular Therapies, Inc. (ITI), today announced it has initiated a sleep maintenance insomnia (SMI) Phase...


Dec 19, 2007, 00:00 ET Intra-Cellular Therapies Presents Preclinical Data From Schizophrenia and Sleep Maintenance Programs

NEW YORK, Dec. 19 /PRNewswire/ -- Intra-Cellular Therapies, Inc. (ITI) presented preclinical data on ITI-007, its first in class dual 5HT2A...


Jun 21, 2007, 01:00 ET Intra-Cellular Therapies Initiates Phase I Clinical Program for Schizophrenia and Sleep Maintenance Disorders

NEW YORK, June 21 /PRNewswire/ -- Intra-Cellular Therapies, Inc., today announced it has initiated Phase I clinical trials for ITI-007, the...


Jun 01, 2005, 01:00 ET Intra-Cellular Therapies, Inc. Receives Exclusive License for Central Nervous System Compounds from Bristol-Myers Squibb Company

NEW YORK, June 1 /PRNewswire/ -- Intra-Cellular Therapies, Inc., (ITI) a privately held biopharmaceutical company focusing on the development of...